Screen readers: Two navigational links to follow.Skip to site navigation.Skip to page content.
The University of Iowa News Services
The University of Iowa News Services Home News Releases UI in the News Subscribe to UI News Contact Us

University of Iowa News Release

 

Feb. 14, 2007

Goldman Receives Grant From Talecris Biotherapeutics

A leading researcher and clinician at Children's Hospital of Iowa within University of Iowa Hospitals and Clinics in Iowa City will receive a "Talents" grant from Talecris Biotherapeutics.

Frederick Goldman, M.D., UI associate professor of pediatrics and director of the Pediatric Immune Disorders Clinic at UI Hospitals and Clinics, was one of seven leading scientific investigators from research institutions around the world selected to receive the grant.

"This was a very competitive grant, with fewer than 10 percent of applications getting funded. The grant was awarded because information gained from our studies should enhance our understanding of how intravenous immunoglobulin works and may provide insight into new applications for this product," Goldman said.

The program is aimed at supporting research and trials that advance knowledge in the usage of intravenous immunoglobulin (IVIG) therapies. IVIG has been shown to be successful in treating a variety of autoimmune and immunodeficiency diseases.

This is the first year that Talecris Biotherapeutics has offered the grant; they have committed $1 million yearly to support the Talents program, with each individual grant being worth up to $150,000.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical-care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology and hemostasis.

STORY SOURCE: Joint Office for Marketing and Communications, University of Iowa Health Care, 200 Hawkins Drive, Room E110 GH, Iowa City, Iowa 52242-1009

MEDIA CONTACTS: Tom Moore, 319-356-3945, thomas-moore@uiowa.edu. Lacy McMahon, Talecris Biotherapeutics, 919-316-6316, lacy.mcmahon@talecris.com. Writer: John Allen